Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC 50 of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.
|Number of pages||5|
|Journal||Biochemical and Biophysical Research Communications|
|Publication status||Published - 2012 Jan 6|
Bibliographical noteFunding Information:
This study was partly supported by grants from the National Research Foundation of Korea funded by the Korean Government (MEST; 2009-0092964, 2010-0017984, F01-2009-000-10183-0), the Translational Research Center for Protein Function Control, KRF (2009-0083522), the Center for Food and Drug Materials of Agriculture Science & Technology Development (2011-8-1178), Rural Development Administration, National R&D Program, Ministry of Health & Welfare, and the Brain Korea 21 Project, Republic of Korea.
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Cell Biology